Illumina, Roche accused of infringing genetic testing patents
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 December 2020 Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
23 September 2020 Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.
17 January 2020 A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
24 December 2020 Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
23 September 2020 Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.
17 January 2020 A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
24 December 2020 Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
23 September 2020 Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.
17 January 2020 A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
